| 1 |
29531130 | Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. | 2018 Jun |
14 |
| 2 |
26284338 | TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. | 2015 Sep 1 |
1 |
| 3 |
25484594 | Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. | 2014 |
1 |
| 4 |
22194527 | TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma. | 2012 Feb |
9 |
| 5 |
22050093 | Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness. | 2011 Dec |
2 |
| 6 |
19309506 | TLE3 as a candidate biomarker of response to taxane therapy. | 2009 |
1 |